Cargando…

Starting a pharmacovigilance program within a teaching hospital: Challenges and experiences from Lalitpur, Nepal

Pharmacovigilance plays an important role in the rational use of medicines by providing information about adverse drug reactions (ADRs) in the general population. Knowledge of ADRs caused by drugs is important for effective treatment. KIST Medical College has recently joined the national pharmacovig...

Descripción completa

Detalles Bibliográficos
Autores principales: Jha, Nisha, Bajracharya, Omi, Shrestha, Rojeena, Thapa, Harish Singh, Shankar, Pathiyil Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dr. Zaheer-Ud-Din Babar 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471166/
https://www.ncbi.nlm.nih.gov/pubmed/23093871
_version_ 1782246377719332864
author Jha, Nisha
Bajracharya, Omi
Shrestha, Rojeena
Thapa, Harish Singh
Shankar, Pathiyil Ravi
author_facet Jha, Nisha
Bajracharya, Omi
Shrestha, Rojeena
Thapa, Harish Singh
Shankar, Pathiyil Ravi
author_sort Jha, Nisha
collection PubMed
description Pharmacovigilance plays an important role in the rational use of medicines by providing information about adverse drug reactions (ADRs) in the general population. Knowledge of ADRs caused by drugs is important for effective treatment. KIST Medical College has recently joined the national pharmacovigilance program as a regional center. Clinicians, pharmacists, house officers, nurses and other staff are encouraged to report ADRs to the center. The center started functioning from mid‐July 2008. The objective of this study was to report the various ADRs presented to the center in its first seven months of operation. Doctors and other health care professionals were briefed regarding the ADR reporting system. An ADR reporting form was designed and circulated to all the departments in the hospital. The reported reactions were analyzed for causality, severity and preventability using different scales. To date, thirty six ADRs have been reported. The majority of the reports (23) were from the Department of Medicine. Other departments like Pediatrics, Obstetrics‐Gynecology and Radiology have also reported ADRs. As per the causality assessment, 21 (58.3%) reports were found to be “possible” and 15 (41.6%) were found to be probably associated with the named medication. With respect to severity, 17 (47.2%) reports were mild and 19 (52.7%) were moderate. As per the preventability scale, 8 (22.2%) ADRs were definitely preventable while 28 (77.7%) were not preventable. The ADRs are reported to the Uppsala Monitoring Center through Vigiflow via the Department of Drug Administration.
format Online
Article
Text
id pubmed-3471166
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dr. Zaheer-Ud-Din Babar
record_format MEDLINE/PubMed
spelling pubmed-34711662012-10-23 Starting a pharmacovigilance program within a teaching hospital: Challenges and experiences from Lalitpur, Nepal Jha, Nisha Bajracharya, Omi Shrestha, Rojeena Thapa, Harish Singh Shankar, Pathiyil Ravi South Med Rev Short Report Pharmacovigilance plays an important role in the rational use of medicines by providing information about adverse drug reactions (ADRs) in the general population. Knowledge of ADRs caused by drugs is important for effective treatment. KIST Medical College has recently joined the national pharmacovigilance program as a regional center. Clinicians, pharmacists, house officers, nurses and other staff are encouraged to report ADRs to the center. The center started functioning from mid‐July 2008. The objective of this study was to report the various ADRs presented to the center in its first seven months of operation. Doctors and other health care professionals were briefed regarding the ADR reporting system. An ADR reporting form was designed and circulated to all the departments in the hospital. The reported reactions were analyzed for causality, severity and preventability using different scales. To date, thirty six ADRs have been reported. The majority of the reports (23) were from the Department of Medicine. Other departments like Pediatrics, Obstetrics‐Gynecology and Radiology have also reported ADRs. As per the causality assessment, 21 (58.3%) reports were found to be “possible” and 15 (41.6%) were found to be probably associated with the named medication. With respect to severity, 17 (47.2%) reports were mild and 19 (52.7%) were moderate. As per the preventability scale, 8 (22.2%) ADRs were definitely preventable while 28 (77.7%) were not preventable. The ADRs are reported to the Uppsala Monitoring Center through Vigiflow via the Department of Drug Administration. Dr. Zaheer-Ud-Din Babar 2009-04-16 /pmc/articles/PMC3471166/ /pubmed/23093871 Text en
spellingShingle Short Report
Jha, Nisha
Bajracharya, Omi
Shrestha, Rojeena
Thapa, Harish Singh
Shankar, Pathiyil Ravi
Starting a pharmacovigilance program within a teaching hospital: Challenges and experiences from Lalitpur, Nepal
title Starting a pharmacovigilance program within a teaching hospital: Challenges and experiences from Lalitpur, Nepal
title_full Starting a pharmacovigilance program within a teaching hospital: Challenges and experiences from Lalitpur, Nepal
title_fullStr Starting a pharmacovigilance program within a teaching hospital: Challenges and experiences from Lalitpur, Nepal
title_full_unstemmed Starting a pharmacovigilance program within a teaching hospital: Challenges and experiences from Lalitpur, Nepal
title_short Starting a pharmacovigilance program within a teaching hospital: Challenges and experiences from Lalitpur, Nepal
title_sort starting a pharmacovigilance program within a teaching hospital: challenges and experiences from lalitpur, nepal
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471166/
https://www.ncbi.nlm.nih.gov/pubmed/23093871
work_keys_str_mv AT jhanisha startingapharmacovigilanceprogramwithinateachinghospitalchallengesandexperiencesfromlalitpurnepal
AT bajracharyaomi startingapharmacovigilanceprogramwithinateachinghospitalchallengesandexperiencesfromlalitpurnepal
AT shrestharojeena startingapharmacovigilanceprogramwithinateachinghospitalchallengesandexperiencesfromlalitpurnepal
AT thapaharishsingh startingapharmacovigilanceprogramwithinateachinghospitalchallengesandexperiencesfromlalitpurnepal
AT shankarpathiyilravi startingapharmacovigilanceprogramwithinateachinghospitalchallengesandexperiencesfromlalitpurnepal